A study examining nicotine delivery in e-cigs and normal cigarettes

  • Research type

    Research Study

  • Full title

    A Randomised Controlled Single-centre Open-label Pharmacokinetic Study to Examine Nicotine Delivery from Different Variants of an E-cigarette and a Conventional Cigarette in Healthy subjects.

  • IRAS ID

    254373

  • Contact name

    Ezanul Wahab

  • Contact email

    ezanul.wahab@simbecorion.com

  • Sponsor organisation

    British American Tobacco (Investments) Ltd

  • Duration of Study in the UK

    0 years, 1 months, 21 days

  • Research summary

    This study is an open-label, randomised pharmacokinetic study to examine the nicotine delivery and levels in the bloodstream of different variations of an e-cigarette and a conventional cigarette.

    Cigarette smoking has been identified as a contributing factor to numerous illnesses including lung cancer, chronic obstructive lung disease and heart disease. The health risks associated with cigarette smoking are known to be due to chemicals toxicants in cigarette smoke, which can lead to changes in the body, causing disease. Nicotine is primarily responsible for the addictive properties of cigarette smoking.

    This study has been developed by the Sponsor in order to assist the development of an alternative approach to conventional cigarettes, by developing new products which may have the potential to reduce some of the risks of tobacco-related diseases namely “Next Generation Products” (NGP). These are nicotine-delivering devices such as electronic inhalable vapour products (e-cigarettes).

    The purpose of this study is to determine the levels of nicotine in the bloodstream when delivered from variations of 2 e-cigarettes containing different concentrations of nicotine and a conventional cigarette when smoked ad libitum or following a fixed 'puff' regime.

    This study will be conducted in 24 male and female subjects who are all daily e-cigarette users and active smokers. The study will consist of a screening visit, 8 treatment periods (of 1 day in duration, 12 hour washout between each period) and a follow up phone call.

  • REC name

    Wales REC 2

  • REC reference

    18/WA/0353

  • Date of REC Opinion

    25 Oct 2018

  • REC opinion

    Further Information Favourable Opinion